Jennifer L Craigen

Title: Jennifer L Craigen: Innovator in Antigen Binding Proteins

Introduction

Jennifer L Craigen is a prominent inventor based in Stevenage, GB. She has made significant contributions to the field of biotechnology, particularly in the development of antigen binding proteins. With a total of 3 patents to her name, her work has the potential to impact medical treatments significantly.

Latest Patents

Jennifer's latest patents focus on antigen binding proteins that specifically bind to B Cell Maturation Antigen (BCMA). These inventions aim to inhibit the binding of BAFF and APRIL to the BCMA receptor, which is crucial for various therapeutic applications. The patents also disclose pharmaceutical compositions, screening methods, and medical treatment methods related to these proteins.

Career Highlights

Jennifer is currently associated with Glaxo Group Limited, where she continues to advance her research and innovations. Her work is instrumental in the development of new therapeutic strategies that could benefit patients with conditions related to B cell maturation.

Collaborations

Throughout her career, Jennifer has collaborated with notable colleagues, including Paul Algate and Stephanie Jane Clegg. These collaborations have enriched her research and contributed to the success of her inventions.

Conclusion

Jennifer L Craigen is a remarkable inventor whose work in antigen binding proteins holds promise for future medical advancements. Her contributions to biotechnology are noteworthy and continue to inspire innovation in the field.